

1 COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-
2 based study

3 Short title: COVID-19 antibody seroprevalence in Duhok, Iraq

4 Authors

5 Nawfal R Hussein^{1*}, Amer A Balatay², Ibrahim A Naqid¹, Shakir A Jamal¹, Narin A
6 Rasheed³, Alind N Ahmed⁴, Reving S Salih⁴, Ahmed S Mahdi⁵, Sabeeha A Mansour⁴,
7 Shaveen Mahdi⁶, Nashwan Ibrahim⁷, Dildar H Musa⁷, Zana SM. Saleem⁷

8 Affiliations

9 ¹ Department of Biomedical Sciences, College of Medicine, University of Zakho,
10 Kurdistan Region, Iraq

11 ² Department of pharmacology and clinical pharmacy, College of pharmacy, University
12 of Duhok, Kurdistan Region, Iraq

13 ³Akre Technical Institute, Duhok Polytechnic University, Duhok, Kurdistan Region, Iraq

14 ⁴Azadi Teaching Hospital, Duhok, Kurdistan Region of Iraq

15 ⁵Childhood Friends Hospital of Amedi, Kurdistan Region of Iraq

16 ⁶Duhok Maternity Hospital, Duhok, Kurdistan Region of Iraq

17 ⁷College of Medicine, University of Duhok, Kurdistan Region, Iraq

18 * Corresponding author

19 Prof Dr Nawfal R Hussein
20 College of Medicine, University of Zakho,
21 Duhok, Kurdistan region, Iraq
22 P.O Box12
23 Mobile: 009647504454974
24 Email: nawfal.hussein@uoz.edu.krd

25

26

27 **Abstract**

1

28 **Objective**

29 This population-based study aimed to evaluate the seroprevalence of antibodies to
30 SARS-CoV-2 in Duhok City, Kurdistan Region of Iraq.

31 **Methods**

32 We analyzed the national COVID-19 database that contains data regarding COVID-19
33 testing, management, and clinical outcomes in Duhok. For this study, different
34 subdistricts within each district of Duhok were considered distinct clusters. Blood
35 samples were collected from and questionnaires were administered to eligible and
36 consenting participants who were members of different families from the subdistricts.
37 Immunoassays were conducted to detect antibodies against SARS-CoV-2, and the
38 associations between certain variables were investigated.

39 **Results**

40 The average number cases of COVID-19 before November 2020 was 23141 ± 4364 ,
41 which was significantly higher than the average number of cases between November
42 2020 and February 2021 (3737 ± 2634 ; $P = 0.001$). A total of 743 individuals agreed to
43 participate and were enrolled in the study. Among the participants, 465/743 (62.58%)
44 were found to have antibodies against severe acute respiratory syndrome coronavirus
45 2. Among the participants with antibodies, 262/465 (56.34%) denied having any history
46 of COVID-19-related symptoms. The most common symptom was fever (81.77%),
47 followed by myalgia (81.28%). We found that antibody levels increased steadily with
48 age (Pearson correlation coefficient = 0.117; $P = 0.012$). A significant association was

49 found between antibody levels and the presence of symptoms ($P = 0.023$; odds ratio =
50 1.0023; 95% confidence interval = 1.0002-1.0061).

51 **Conclusions**

52 A significant reduction in the number of COVID-19 cases was observed. This might be
53 due to the high prevalence of SARS-CoV-2 antibodies in Duhok. However, infection-
54 prevention measures should be followed as it remains unclear whether acquired
55 immunity is protective against reinfection. It expected that the infection rates during the
56 next wave will not be as high as the first wave due to the high infection rate in the
57 society.

58

59 **Introduction**

60 Since the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
61 the coronavirus disease (COVID-19) pandemic has been considered the most important
62 healthcare crisis in the world. COVID-19 is an emerging infectious respiratory disease
63 that was discovered in Wuhan, China, in December 2019 and rapidly spread worldwide
64 [1]. The World Health Organization declared the COVID-19 outbreak a global pandemic
65 on March 11, 2020. Since the appearance of the first few cases in Iraq, strict measures
66 were put in place in the Kurdistan Region to stop the spread of infection [2]. The
67 implementation of these measures began on March 1, 2020, and continued until May
68 21, 2020. After the measures were relaxed, a sharp increase in morbidity and mortality
69 was recorded [3,4]. Despite this, there was an unwillingness in society to follow the
70 social-distancing instructions [5]. In addition to a widely held belief that the COVID-19
71 pandemic is a hoax, education losses; widespread job losses; and food insecurity
72 caused people not to adhere to the infection-containment measures [5]. The increase in
73 morbidity and mortality started in mid-June 2020 and continued until October 2020.
74 However, in November 2020, a significant reduction in the number of new COVID-19
75 cases was observed. This was unlikely to be the end of a wave of the COVID-19
76 pandemic in the Kurdistan Region because a majority of the residents in this area do
77 not follow the prevention guidelines, and there are no specific measures being imposed
78 by the Kurdistan Regional Government. One theory explaining this reduction in the
79 number of cases is the achievement of herd immunity, which may play a role in slowing
80 down the transmission of the virus. Herd immunity can be defined as the reduction in
81 the number of infections or disease among the unimmunized individuals of a population

82 as a result of previous infection or immunization in a proportion of individuals of the
83 population [6]. It can be determined by testing a sample of a population for the presence
84 of immune markers [6]. The aim of this population-based study was to evaluate the
85 seroprevalence of antibodies to SARS-CoV-2 among people in Duhok City.

86 **Materials and methods**

87 **Data source**

88 For a national project, all data regarding COVID-19 testing, management, and clinical
89 outcomes in Duhok were reported and registered in a COVID-19 database. The COVID-
90 19 database contains information regarding all the confirmed cases of COVID-19 in the
91 city, showing the results of reverse-transcription polymerase chain reaction testing. In
92 addition, the database covers the number of tests performed, number of suspected
93 cases, cure rate, case fatality rates, and clinical outcomes. The data were analyzed to
94 confirm the decline in the number of cases in the city.

95 **Study sampling**

96 Regional representation was achieved by dividing the city into five districts, and
97 sampling was performed based on population proportions. Because of considerable
98 differences in population density among the different geographic regions of Duhok, we
99 included samples from both urban and rural populations. Random samples were
100 selected using multistage cluster sampling. First, within each district, different
101 subdistricts were considered to be distinct clusters. Subdistricts are known regions
102 within districts with clear boundaries of the city. Second, housing censuses of

103 households in the selected clusters were conducted by a sample-collecting team.
104 General information on the number of families and family members was collected. Then,
105 a number of families within each region were chosen and asked whether they would
106 agree to participate. If a family did not agree to participate, they were excluded from the
107 study. Finally, from each selected family, two people were randomly chosen to
108 participate. The people who did not agree to participate or those who were absent on
109 the day of sample collection were excluded from the study and replaced with other
110 participants.

111 **Sample size**

112 When we started the study, an increasing number of unpublished studies reported that
113 the prevalence of COVID-19 had reached 50% in Duhok City, and because there had
114 been no previous reports of the prevalence of the infection in the city, a prevalence of
115 50% was used to calculate the sample size. With a confidence interval of 99%, margin
116 of error of 0.05, design effect of 1, and expected response rate of 80%, the minimum
117 sample size calculated was 830.

118 **Inclusion criteria**

119 A person was eligible to be included in the study if the person was at least 16 years old,
120 was a resident of one of the considered districts, had been living at a specific address
121 for at least 6 months, and agreed to participate in the study.

122 **Sample collection**

123 Samples were collected between January 10, 2021, and January 30, 2021. A week
124 before the survey, the team members who had not been trained on the use of personal
125 protective equipment attended a training session on their use. All the team members of
126 the sample-collection team attended a training session regarding the blood-sampling
127 process employed in this study and the administration of a questionnaire. The persons
128 who were eligible for inclusion in the study were interviewed and they completed a
129 questionnaire. Subsequently, a member of the team explained the procedures for
130 sample collection. Then, 5-10 cm³ of venous blood samples were collected using 10-
131 cm³ syringes. The samples were immediately transported to the research center, and
132 sera were separated from the blood and kept frozen at -20°C.

133 **SARS-CoV-2 antibody measurement**

134 Elecsys Anti-SARS-CoV-2 (Roche Diagnostics International Ltd, Rotkreuz, Switzerland),
135 which is an immunoassay for the in vitro qualitative detection of antibodies (including
136 IgG) to SARS-CoV-2, was used to determine antibody levels. The assay was performed
137 according to the manufacturer's instructions. According to the manufacturer, a cutoff
138 index ≥ 1.0 indicates a positive result.

139 **Statistics**

140 When variables were continuous, linear regression was used to study the relationship
141 between the variable and outcome. A Chi-square test was used to analyze categorical
142 data. Pearson's correlation coefficients were calculated to study the relationship
143 between two continuous variables. Statistical analysis was performed using Minitab 17.
144 P values < 0.05 were considered significant.

145 **Ethics**

146 The study protocol and method of obtaining consent were approved by the Ethics and
147 Scientific Committee of the University of Zakho's College of Medicine. Informed consent
148 was obtained from all participants.

149 **Results**

150 **Data analysis**

151 The analysis of the national COVID-19 database showed a sharp decrease in the
152 percentage of new cases (Fig 1). The average number of COVID-19 cases before
153 November 2020 was 23141 ± 4364 , which was significantly higher than the average
154 number of cases between November 2020 and February 2021 (3737 ± 2634 ; $P =$
155 0.001).

156 **Fig 1. Reduced number of COVID-19 cases.** Significant reduction in the number of
157 cases in Duhok, based on the incidence of reported cases in the city.

158 **Prevalence of COVID-19**

159 A total of 903 individuals were interviewed in this study, which considered 411
160 households in five districts of Duhok; 192 individuals lived in the city center, and the rest
161 were from peripheral towns and villages. In this study, 160 individuals did not agree to
162 participate and were excluded from further analysis. A total of 743 individuals agreed to
163 participate and were enrolled in the study. The average age of the participants was 34.6

164 ± 13.9 , and (392/743) 52.8% of the participants were female. Among the participants,
165 519/743 were married and (164/743) 22.1% had a history of chronic diseases.

166 **Antibody positivity and association between host factors and** 167 **antibody levels**

168 Among the participants, 465/743 (62.58%) tested positive for antibodies. Among the
169 participants with antibodies, 262/465 (56.34%) denied having any history of COVID-19
170 related symptoms. A total of 203/465 (43.66%) participants had a history of different
171 symptoms (Table 1). The average duration of symptoms was 11.81 ± 10.80 days, and
172 the most common symptom was fever (81.77%), followed by myalgia (81.28%) and loss
173 of smell (56.79%). Among the participants who had experienced symptoms, 21.67%
174 reported having experienced diarrhea (Table 1). The presence of symptoms was
175 significantly higher among married participants ($P=0.046$), participants with a history of
176 chronic diseases ($P = 0.001$), and older participants ($P = 0.0015$) (Table 2).

177 **Table 1. Characteristics of participants who tested positive for antibodies**

Characteristics		No. of participants	%
Sex: Female		264	56.77
Marital status: Married		335	72.04
Chronic diseases (Yes)		113	24.3
Symptoms		203	43.87
Symptoms	Fever	166	81.77

	Myalgia	165	81.28
	Loss of smell	114	56.79
	Loss of taste	95	46.79
	Shortness of breath	89	43.84
	Cough	41	20.19
	Diarrhea	44	21.67
	Headache	40	19.7
	Duration of symptoms (Days + standard deviation)	11.81 ± 10.80	
	Age	34.40 ± 13.73	

178

179 Pearson's correlation coefficient was calculated to explore the relationship between
180 antibody levels and the age of the participants. We found that antibody levels increased
181 steadily with age (Pearson's correlation coefficient = 0.117; P = 0.012) (Fig 2A). No
182 association was found between the time interval between SARS-CoV-2 detected and
183 testing date (Pearson's correlation coefficient = 0.029; P = 0.681) (Fig 2B). Linear
184 regression analysis was used to investigate antibody levels, sex, marital status, and the
185 presence of symptoms (Table 2). A significant association was found between antibody
186 levels and the presence of symptoms (P = 0.023; odds ratio = 1.0023; 95% confidence
187 interval = 1.0002-1.0061). No significant associations were found between antibody
188 levels and sex or marital status (Table 2).

189 **Fig 2. Association of age and time interval before testing with antibody responses**
190 **to SARS-CoV-2.**

191 (A) Age was associated with antibody responses to SARS-CoV-2. Analysis through
192 calculation of Pearson’s correlation coefficient was used to investigate the relationship
193 between age and antibody levels. (B) Time interval before testing was not associated
194 with antibody responses to SARS-CoV-2. Analysis through calculation of Pearson’s
195 correlation coefficient was used to investigate the relationship between time intervals

	Asymptomatic Positive (n=262)		Symptomatic Positive (n=203)		P value	95% CI	OR
	No.	%	No.	%			

196 and antibody levels.

197

198 **Table 2. Associations between different factors and antibody levels**

199

Sex: Female	152	57.8	111	54.4	0.266	0.8-2	1
Chronic disease (Yes)	37	14.1	76	37.3	0.001	0.2-0.4	0.3
Marital status (Married)	179	68.1	154	75.5	0.046	0.5-1	0.7
Age (Year \pm SD)	32.6 \pm 13.5		36.8 \pm 13.8		0.0015	1.01-1.05	1.022

200 SD, standard deviation; CI, confidence interval; OR, odds ratio

201 Discussion

202 Since the emergence of the COVID-19 pandemic, scientific communities worldwide
203 have aimed to control the spread of the infection. The achievement of herd immunity
204 has been highlighted as an option for controlling the pandemic. Certain questions
205 remain regarding whether herd immunity is derived from natural infection and what
206 proportion of a population must attain immunity through infection for the effect of
207 protection to be achieved. Since the basic reproduction number for COVID-19 has been
208 estimated to lie within the range of 2-4, the herd immunity level for COVID-19 is
209 believed to lie between 50% and 75% [7]. In one study, the authors assumed that that
210 all individuals are equally susceptible and equally infectious, and the threshold to
211 achieve herd immunity of SARS-CoV-2 was calculated to range between 50% and 67%
212 [8]. In a study conducted in Bangladesh, the computation model indicated that the herd
213 immunity threshold can be reduced from 60% to 31% by categorizing the population into
214 age groups [9]. In Duhok, strict measures were imposed by the government to control
215 the spread of the infection [2]; however, mounting economic and political pressures

216 pressurized the government into relaxing the measures. The relaxation of the measures
217 took place at a rapid pace, without any specific plans [5]. The government's actions in
218 this regard were then limited to the giving of instructions, and those who did not follow
219 the instructions were not penalized. The number of COVID-19 cases increased sharply
220 until November 2020, when a sharp decrease in the number of cases was observed
221 [3,4]. Our study shows that the number of cases decreased significantly in the following
222 months. This is unlikely to be the end of a wave because no specific measures were
223 taken, and people did not follow the social-distancing instructions [3,5]. We aimed to
224 investigate this decline in the number of cases. In this study, the prevalence of COVID-
225 19 was found to be > 62%. Most significantly, in the present study, the number of
226 infections was found to be much greater than the registered number of cases by the
227 Government, which was approximately 3% [10]. This finding implies that there were
228 approximately 20 cases in Duhok City for each registered case. Thus, the number of
229 registered cases was 20-fold lower than the number of COVID-19 cases predicted by
230 this study. This may be due to a great number of individuals with infection being
231 asymptomatic or cases not being reported because of the stigma associated with the
232 infection. This ascertainment and difference between our results and registered cases is
233 a crucial because infection-to-case ratios are considered in many projection and
234 epidemiological models in order to calculate fatality rates and understand which stage
235 an epidemic is in [11]. Additionally, such an infection-to-case ratio may suggest that the
236 fatality rate might be much higher. Another important implication of this study's findings
237 is that with such a high prevalence, it is unlikely that the number of cases will increase
238 sharply again to previous levels recorded during the first wave. Since antibody titers

239 may decline after a period of time, the prevalence of SARS-CoV-2 infection may be
240 higher than what we reported. It is worth mentioning that it is unclear whether post-
241 infection immunity, specifically that provided by antibodies, protects individuals or
242 generates herd immunity, and further studies are required to explore this. Furthermore,
243 more than 56% of the participants who tested positive for antibodies were
244 asymptomatic. Although the exact role of asymptomatic individuals in the transmission
245 of the virus is not clear [12], the great number of asymptomatic individuals with SARS-
246 CoV-2 infection may have played a role in the widespread transmission of the virus in
247 Duhok City.

248 Next, we studied the factors that may impact the production of antibodies. In agreement
249 with previous reports [13,14], we found that older age was associated with higher
250 antibody levels. This may be because older individuals are more susceptible to severe
251 infection. In contrast to a previous report [15], no association was found between sex
252 and antibody levels. In agreement with a previous study [13,16], we found an
253 association between the presence of symptoms and higher antibody levels. Further
254 investigation is needed to study the effects of different factors and their association with
255 antibody levels. It has been previously shown that antibody levels may decline over time
256 [17,18]. In our study, no association was found between the time interval before testing
257 and antibody levels. This may be partially explained by differences in human genetics,
258 virus genetic makeup, and environmental factors. It is worth mentioning that our study
259 was cross-sectional; therefore, the kinetics of antibody response over time could not be
260 investigated.

261 Our study had certain limitations. First, we could not ascertain the representativeness
262 of SARS-CoV-2 antibodies in groups with possibly high prevalence, such as healthcare
263 workers and nursing-home residents and workers. Additionally, we could not reach
264 remote villages due to transportation difficulties, particularly those caused by the snowy
265 winter weather.

266 In conclusion, a significant reduction in the number of COVID-19 cases was observed.
267 This may be due to the high prevalence of SARS-CoV-2 antibodies in Duhok. To control
268 the spread of COVID-19, it is extremely important for members of society to follow
269 social-distancing measures. It expected that the infection rates during the second wave
270 will not be as high as the first wave due to the high infection rate in the society. Locally
271 derived population prevalence estimates should be used to develop infection control
272 plans.

273

274 **Acknowledgments**

275 We would like to thanks Amer Lab staff for the technical support. We Acknowledge the
276 role of Mr Muhammed Salih for helping in recruiting participants into the project.

277 **References**

278

- 279 1. Odone A, Delmonte D, Scognamiglio T, Signorelli C. COVID-19 deaths in Lombardy, Italy: data in
280 context. *Lancet Public Health*. 2020;Volume 5: e310. doi: [10.1016/S2468-2667\(20\)30099-2](https://doi.org/10.1016/S2468-2667(20)30099-2).
- 281 2. Hussein NR, Naqid IA, Saleem ZSM. A retrospective descriptive study characterizing coronavirus
282 disease epidemiology among people in the Kurdistan Region, Iraq. *Mediterr J Hematol Infect Dis*.
283 2020;12(1): e2020061. DOI: [10.4084/MJHID.2020.061](https://doi.org/10.4084/MJHID.2020.061).
- 284 3. Hussein NR, Naqid IA, Saleem ZSM, Almizori LA, Musa DH, Ibrahim N. A sharp increase in the
285 number of COVID-19 cases and case fatality rates after lifting the lockdown in Kurdistan region of Iraq.
286 *Ann Med Surg (Lond)*. 2020;57: 140-142. DOI: [10.1016/j.amsu.2020.07.030](https://doi.org/10.1016/j.amsu.2020.07.030).
- 287 4. Hussein NR, Naqid IA, Saleem ZSM, Musa DH, Ibrahim N. The Impact of Breaching Lockdown on
288 the Spread of COVID-19 in Kurdistan Region, Iraq. *Avicenna J Clin Microbiol Infect*. 2020;7(1): 34-35. DOI:
289 [10.34172/ajcmi.2020.07](https://doi.org/10.34172/ajcmi.2020.07).
- 290 5. Hussein NR. The Role of Self-Responsible Response Versus Lockdown Approach in Controlling
291 COVID-19 Pandemic in Kurdistan Region of Iraq. *Int J Infect*. 2020;7(4). DOI: [10.5812/iji.107092](https://doi.org/10.5812/iji.107092).
- 292 6. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. *Eur J Epidemiol*.
293 2000;16(7): 601-606. doi: [10.1023/A:1007626510002](https://doi.org/10.1023/A:1007626510002).
- 294 7. Britton T, Ball F, Trapman P. The disease-induced herd immunity level for Covid-19 is
295 substantially lower than the classical herd immunity level. *medRxiv*. 2020.05.06.20093336. doi:
296 [10.1101/2020.05.06.20093336](https://doi.org/10.1101/2020.05.06.20093336).
- 297 8. Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-CoV-2 Control. *JAMA*.
298 2020;324(20): 2095-2096. doi: [10.1001/jama.2020.20892](https://doi.org/10.1001/jama.2020.20892).

- 299 9. Hoque ME, Islam MS, Amin MR, Das SK, Mitra DK. Adjusted Dynamics of COVID-19 Pandemic
300 due to Herd Immunity in Bangladesh. medRxiv. 2020.09.03.20186957. doi:
301 [10.1101/2020.09.03.20186957](https://doi.org/10.1101/2020.09.03.20186957).
- 302 10. MoH. Latest Information about Coronavirus (COVID-19): MoH; 2020 [cited 2020 01/2/2021].
303 Available: <https://gov.krd/coronavirus-en/>.
- 304 11. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody
305 seroprevalence in Santa Clara County, California. Int J Epidemiol. 2021. doi: [10.1093/ije/dyab010](https://doi.org/10.1093/ije/dyab010).
- 306 12. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of
307 asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-
308 analysis. Off J Assoc Med Microbiol Infect Dis Can. 2020;5(4): 223-234. doi: [10.3138/jammi-2020-0030](https://doi.org/10.3138/jammi-2020-0030).
- 309 13. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization
310 drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest.
311 2020;130(11): 6141-6150. doi: [10.1172/JCI142004](https://doi.org/10.1172/JCI142004).
- 312 14. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the
313 Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With
314 COVID-19. Front Mol Biosci. 2020;Volume 7: 157. doi: [10.3389/fmolb.2020.00157](https://doi.org/10.3389/fmolb.2020.00157).
- 315 15. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts
316 immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7): 442-447. doi:
317 [10.1038/s41577-020-0348-8](https://doi.org/10.1038/s41577-020-0348-8).
- 318 16. Marklund E, Leach S, Axelsson H, Nyström K, Norder H, Bemark M, et al. Serum-IgG responses to
319 SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLOS ONE.
320 2020;15(10): e0241104. doi: [10.1371/journal.pone.0241104](https://doi.org/10.1371/journal.pone.0241104).

321 17. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and
322 decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in
323 humans. Nat Microbiol. 2020;5(12): 1598-1607. doi: [10.1038/s41564-020-00813-8](https://doi.org/10.1038/s41564-020-00813-8).

324 18. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing
325 antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12(1): 844. doi:
326 [10.1038/s41467-021-21111-9](https://doi.org/10.1038/s41467-021-21111-9).

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369



